Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported encouraging interim results from its ongoing SEISMiC C Phase 2 trial evaluating istaroxime in patients with SCAI Stage C cardiogenic shock, …
Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced encouraging top-line results from a Phase 2a trial evaluating ATI-2138, its oral investigational treatment targeting moderate-to-severe atopic dermatitis (AD). The study …
Aclaris Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis Trial Read More
WILMINGTON, DE — AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, delivered a statistically significant and clinically meaningful improvement in overall survival for patients …
AstraZeneca’s TAGRISSO Combo Shows Strong Survival Benefit in EGFR-Mutated Lung Cancer Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial evaluating firmonertinib as a first-line treatment …
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data Read More
NEWTOWN, PA — Helius Medical Technologies (NASDAQ: HSDT) has reported promising results from its Stroke Registrational Program (SRP), paving the way for a potential U.S. regulatory submission later this year. …
Helius Medical Reports Positive Trial Results for Stroke Therapy, Eyes FDA Submission Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating OCU410ST, a gene therapy candidate designed …
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy Read More
KING OF PRUSSIA, PA — XyloCor Therapeutics has dosed the first patient in its Phase 2b EXACT-2 trial evaluating XC001 (encoberminogene rezmadenovec), a novel gene therapy designed to help patients …
XyloCor Doses First Patient in Pivotal Gene Therapy Trial for Refractory Angina Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced an amended collaboration and licensing agreement with Torii Pharmaceutical Co. Ltd. to initiate a global Phase 3 clinical trial …
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the publication of groundbreaking results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association …
Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has achieved a major milestone in its Phase 2 SEISMiC C study, announcing the planned enrollment of 20 patients for its interim …
Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment Read More